Black checkmark with a sparkle and a curved line underneath on a white background.
Company

TG THERAPEUTICS, INC.

Ticker
TGTX
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include TG Therapeutics’ Q3 2026 financial results release with raised full-year revenue guidance, continued enrollment progress in Phase 3 trials for subcutaneous ublituximab, and ongoing commercialization efforts for BRIUMVI in the U.S. and Europe.

Recent developments:
  • TG Therapeutics reported third quarter 2026 financial results and raised full-year revenue guidance, reflecting commercial progress for BRIUMVI and operational execution [N2].
  • The company’s Q3 2026 earnings call provided detailed updates on clinical trial enrollment, including over 75% enrollment in the Phase 3 pivotal program for subcutaneous ublituximab [N1].
  • TG Therapeutics announced that BRIUMVI continues to be commercially available in multiple countries outside the U.S. through its partnership with Neuraxpharm [N3].
  • The company highlighted ongoing efforts to expand patient awareness and support through initiatives such as the Next In MS platform [N4].
Overview

TG Therapeutics is a biotechnology company specializing in the acquisition, development, and commercialization of therapies targeting B-cell mediated diseases, with a primary focus on multiple sclerosis (MS). The company’s flagship product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved by the FDA in December 2022 for treating adults with relapsing forms of MS. BRIUMVI is administered intravenously every 24 weeks and has demonstrated efficacy in reducing relapse rates and MRI lesion activity in Phase 3 trials. TG Therapeutics launched BRIUMVI commercially in the U.S. in January 2023 and has partnered with Neuraxpharm for ex-U.S. commercialization, with availability in several European countries. The company is conducting Phase 3 trials for a subcutaneous formulation of ublituximab and is developing a CAR T cell therapy, azer-cel, for progressive MS. TG Therapeutics maintains a patient-first culture and pursues expansion of indications and pipeline development for B-cell diseases.

Executive summary

TG Therapeutics, Inc. is a commercial-stage biotechnology company focused on treatments for B-cell diseases, primarily multiple sclerosis (MS). Its lead product, BRIUMVI, is FDA-approved for relapsing forms of MS and commercially launched in the U.S. in 2023, with ex-U.S. commercialization underway. The company is advancing subcutaneous formulations and novel therapies like azer-cel in clinical trials. As of September 30, 2026, TG Therapeutics reported $429 million in cash and equivalents, a current ratio of 4.5, net income of $55.5 million, and EPS of $0.39 basic. The company faces risks including market acceptance, competition, regulatory compliance, and pricing pressures. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for TGTX

Bull case model:

TG Therapeutics has established a commercial presence with BRIUMVI in the U.S. and Europe, supported by positive clinical data and patent protection. The ongoing Phase 3 trials for subcutaneous ublituximab and development of azer-cel for progressive MS represent potential avenues for expanding the product portfolio and addressing unmet medical needs. The company’s patient-focused initiatives and collaborations enhance brand recognition and market penetration. Strong liquidity and recent net income indicate operational progress. Continued successful execution of clinical programs and commercialization efforts could enhance the company’s business model visibility and operational scale.

Bear case model:

TG Therapeutics faces risks including limited market acceptance of BRIUMVI amid competition from established therapies, regulatory challenges including post-marketing commitments, and pricing and reimbursement pressures that could constrain revenue growth. The company’s commercial experience is limited, and adverse safety findings or regulatory restrictions could impact product utilization. The biotechnology industry’s competitive landscape includes larger companies with greater resources. Clinical development programs carry inherent uncertainties, and failure to advance pipeline candidates or expand indications could limit future growth. Market dynamics and healthcare policy changes may also affect commercial outcomes.

Moat:

TG Therapeutics’ moat is anchored in its FDA-approved product BRIUMVI, supported by robust Phase 3 clinical trial data demonstrating efficacy and safety in relapsing forms of multiple sclerosis. The company has extended patent protection for BRIUMVI through 2042, providing intellectual property barriers. Its focused expertise in B-cell mediated diseases and a clinical development platform with experience in FDA approvals contribute to competitive advantages. Strategic partnerships for ex-U.S. commercialization and ongoing development of novel formulations and therapies further strengthen its position. However, the biotechnology sector’s inherent risks and competition from larger pharmaceutical companies remain significant challenges.

Risks overview
Risks summary
The most significant risks for TG Therapeutics relate to market acceptance of BRIUMVI, regulatory compliance including post-marketing commitments, and competitive pressures in the biotechnology sector.
Risks details:

• Market Acceptance Risk: BRIUMVI and future products may not achieve broad acceptance among physicians, patients, and payors, limiting revenue potential.
• Regulatory and Compliance Risk: Ongoing regulatory requirements, post-marketing studies, and potential safety issues could result in restrictions or additional costs.
• Competition Risk: The company faces competition from larger pharmaceutical and biotech firms with greater resources and established market presence.
• Pricing and Reimbursement Risk: Government and third-party payor policies may limit pricing flexibility and patient access, impacting sales and profitability.
• Clinical Development Risk: Pipeline candidates including subcutaneous ublituximab and azer-cel face clinical trial and regulatory uncertainties that could affect approval and commercialization.

FINAL FORECAST FOR TGTX

Final take one line
TG Therapeutics is a commercial-stage biotech focused on B-cell diseases with FDA-approved BRIUMVI for MS, advancing clinical programs and commercialization amid regulatory and market risks.
Final take 12 to 24 month view

Business trends: Continued commercialization of BRIUMVI in U.S. and Europe, advancement of subcutaneous ublituximab and azer-cel clinical trials, and patient engagement initiatives.
Execution milestones: Completion of Phase 3 trials for subcutaneous ublituximab, regulatory submissions for simplified dosing, and expansion of commercial footprint.
Key risks: Market acceptance challenges, regulatory compliance and post-marketing commitments, competitive pressures, pricing and reimbursement constraints, and clinical development uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on acquisition, development, and commercialization of novel treatments for B-cell diseases, primarily multiple sclerosis (MS).
  • The company’s lead product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the FDA in December 2022 for treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
  • BRIUMVI is administered as a one-hour intravenous infusion every 24 weeks after a starting dose.
  • The ULTIMATE I & II Phase 3 trials demonstrated BRIUMVI’s superiority over teriflunomide in reducing annualized relapse rate and MRI lesion counts; results were published in the New England Journal of Medicine in August 2022.
  • TG Therapeutics commercially launched BRIUMVI in the U.S. in January 2023 and has a commercialization agreement with Neuraxpharm for ex-U.S. markets, with BRIUMVI launched in Germany and other European countries.
  • The company is conducting a Phase 3 pivotal program evaluating subcutaneous ublituximab compared to IV BRIUMVI, with enrollment over 75% complete as of February 2026.
  • A Phase 3 ENHANCE trial is evaluating a simplified dosing schedule for IV BRIUMVI; enrollment completed in October 2025.
  • TG Therapeutics is developing a CAR T cell therapy, azer-cel, for progressive forms of MS, with a Phase 1 trial initiated and first patient dosed in August 2025.
  • The company completed a $100 million share repurchase program in 2025 and authorized a new $100 million repurchase program.
  • As of September 30, 2026, TG Therapeutics reported cash and equivalents of $429.4 million, short-term investments of $75.3 million, current assets of $1.17 billion, current liabilities of $260.5 million, a current ratio of 4.5, and a cash ratio of 1.94.
  • Net income for the quarter ended September 30, 2026, was $55.5 million with basic EPS of $0.39 and diluted EPS of $0.35.
  • The company faces risks related to market acceptance of BRIUMVI, competition, regulatory requirements including post-marketing commitments, pricing and reimbursement challenges, and potential adverse safety findings post-approval.
  • Recent news includes Q3 2026 earnings release with raised full-year revenue guidance and positive commercial progress for BRIUMVI.
  • The company actively promotes awareness of MS through initiatives such as the Next In MS platform and collaboration with Christina Applegate.
  • TG Therapeutics maintains a patient-first culture and focuses on expanding indications and formulations for BRIUMVI and pipeline development for B-cell mediated diseases.
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-02-27 | 10-K
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-10 | www.nasdaq.com | TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/tg-therapeutics-tgtx-q3-2026-earnings-call-transcript
  • N2 | 2026-11-09 | www.nasdaq.com | TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance | https://www.nasdaq.com/articles/tg-therapeutics-reports-third-quarter-2026-financial-results-and-raises-full-year-revenue
  • N3 | 2026-11-09 | www.nasdaq.com | TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say | https://www.nasdaq.com/articles/tg-therapeutics-tgtx-reports-q3-earnings-what-key-metrics-have-say
  • N4 | 2026-11-09 | www.nasdaq.com | TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates | https://www.nasdaq.com/articles/tg-therapeutics-tgtx-beats-q3-earnings-and-revenue-estimates
  • N5 | 2026-11-06 | www.nasdaq.com | Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down | https://www.nasdaq.com/articles/agenus-q3-earnings-match-estimates-revenues-miss-mark-stock-down
  • N6 | 2026-11-06 | www.nasdaq.com | IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs | https://www.nasdaq.com/articles/iova-q3-earnings-beat-amtagvi-sales-and-lower-rd-costs
  • N7 | 2026-11-05 | www.nasdaq.com | HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth | https://www.nasdaq.com/articles/hrmy-q3-earnings-miss-estimates-higher-costs-despite-wakix-growth
  • N8 | 2026-11-05 | www.nasdaq.com | ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock Up | https://www.nasdaq.com/articles/zts-q3-earnings-top-estimates-2026-profit-outlook-improves-stock
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine